WASHINGTON — President Trump is extensively anticipated to attempt to advance a “most-favored nation” coverage subsequent week in an effort to cut back U.S. drug costs — a transfer that’s prone to considerably rattle the pharmaceutical business, cheer his political base, and, probably, go away open some very massive questions.
The concept behind the coverage, usually talking, is straightforward: It might tie funds for medication in america to costs paid by different high-income international locations, lots of which pay far lower than People for his or her medicines. It’s additionally not a brand new concept: The primary Trump administration tried to set it in movement, just for its plans to be blocked.
However now, having discovered the teachings from that defeat, and with a majority within the Home and the Senate, the administration may face higher odds.
This text is unique to STAT+ subscribers
Unlock this text — plus each day intelligence on Capitol Hill and the life sciences business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
